methyl 3-(4-(phenoxymethyl)phenyl)prop-2-ynoate | 634202-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: methyl 3-(4-(phenoxymethyl)phenyl)prop-2-ynoate
• 英文别名: methyl 4-phenoxymethylphenylpropiolate；Methyl 3-[4-(phenoxymethyl)phenyl]prop-2-ynoate
• CAS: 634202-66-7
• 化学式: C₁₇H₁₄O₃
• 分子量: 266.296
• InChiKey: BQTJUPZJMMPBTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-(4-(phenoxymethyl)phenyl)prop-2-ynoate 在 platinum(IV) oxide 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以72%的产率得到methyl 3-(4-(phenoxymethyl)phenyl)propanoate
  参考文献：
  名称：

  Optimization of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

  摘要：

  A series of alpha-ketooxazoles containing conformational constraints in the flexible C2 acyl side chain of 2 (OL-135) and representative oxazole C5 substituents were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH). Exceptionally potent and selective FAAH inhibitors emerged from the series (e.g., 6, K-i = 200 and 260 pM for rat and rhFAAH). With simple and small C5 oxazole substituents, each series bearing a biphenylethyl, phenoxyphenethyl, or (phenoxymethyl)phenethyl C2 side chain was found to follow a well-defined linear relationship between -log K-i and Hammett sigma(p) of a magnitude (rho = 2.7-3.0) that indicates that the substituent electronic effect dominates, confirming its fundamental importance to the series and further establishing its predictive value. Just as significantly, the nature of the C5 oxazole substituent substantially impacts the selectivity of the inhibitors whereas the effect of the C2 acyl chain was more subtle but still significant even in the small series examined. Combination of these independent features, which display generalized trends across a range of inhibitor series, simultaneously improves FAAH potency and selectivity and can provide exquisitely selective and potent FAAH inhibitors.

  DOI：

  10.1021/jm701210y
• 作为产物：
  描述：

  1-iodo-4-(phenoxymethyl)benzene 、 丙炔酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 以45%的产率得到methyl 3-(4-(phenoxymethyl)phenyl)prop-2-ynoate
  参考文献：
  名称：

  [EN] CARBOXAMIDES DERIVATIVES
  [FR] DERIVES DE CARBOXAMIDES

  摘要：

  本发明涉及作为药物制剂活性成分有用的羧酰胺。本发明的羧酰胺具有IP受体拮抗活性，可用于预防和治疗与IP受体拮抗活性相关的疾病。这些疾病包括泌尿系统疾病或障碍，如：膀胱出口梗阻、膀胱过度活跃、尿失禁、膀胱逼尿肌过度反射、膀胱逼尿肌不稳定、膀胱容量减少、排尿频率、迫切性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺肥大（BPH）、前列腺炎、尿频、夜尿频、尿急、盆腔过敏、尿道炎、盆腔疼痛综合征、前列腺疼痛综合征、膀胱炎或特发性膀胱过敏。本发明的化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病性疼痛、急性疼痛、慢性疼痛、牙痛、经前疼痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为通过IP受体拮抗剂治疗可以缓解这些疾病。

  公开号：

  WO2003106403A1

文献信息

• [EN] CARBOXAMIDES DERIVATIVES<br/>[FR] DERIVES DE CARBOXAMIDES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2003106403A1

  公开（公告）日：2003-12-24

  The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity.Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

  本发明涉及作为药物制剂活性成分有用的羧酰胺。本发明的羧酰胺具有IP受体拮抗活性，可用于预防和治疗与IP受体拮抗活性相关的疾病。这些疾病包括泌尿系统疾病或障碍，如：膀胱出口梗阻、膀胱过度活跃、尿失禁、膀胱逼尿肌过度反射、膀胱逼尿肌不稳定、膀胱容量减少、排尿频率、迫切性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺肥大（BPH）、前列腺炎、尿频、夜尿频、尿急、盆腔过敏、尿道炎、盆腔疼痛综合征、前列腺疼痛综合征、膀胱炎或特发性膀胱过敏。本发明的化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病性疼痛、急性疼痛、慢性疼痛、牙痛、经前疼痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为通过IP受体拮抗剂治疗可以缓解这些疾病。
• Carboxamides derivatives
  申请人：Shimazaki Makoto

  公开号：US20060135613A1

  公开（公告）日：2006-06-22

  The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

  本发明涉及一种作为制药制剂活性成分有用的羧酰胺。本发明的羧酰胺具有IP受体拮抗活性，可用于预防和治疗与IP受体拮抗活性相关的疾病。这些疾病包括以下泌尿系统疾病或疾病：膀胱出口梗阻、过度活动的膀胱、尿失禁、膀胱平滑肌过度反射、膀胱平滑肌不稳定、膀胱容量降低、排尿频率、强迫性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺增生症（BPH）、前列腺炎、尿频、夜尿、尿急、盆腔敏感性、尿道炎、盆腔疼痛综合征、前列腺痛、膀胱炎或特发性膀胱敏感性。本发明化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病理性疼痛、急性疼痛、慢性疼痛、牙痛、经前痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为这些疾病通过使用IP受体拮抗剂治疗得到缓解。
• CARBOXAMIDES DERIVATIVES
  申请人：Bayer HealthCare AG

  公开号：EP1515942A1

  公开（公告）日：2005-03-23
• Optimization of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase
  作者：F. Scott Kimball、F. Anthony Romero、Cyrine Ezzili、Joie Garfunkle、Thomas J. Rayl、Dustin G. Hochstatter、Inkyu Hwang、Dale L. Boger

  DOI：10.1021/jm701210y

  日期：2008.2.1

  A series of alpha-ketooxazoles containing conformational constraints in the flexible C2 acyl side chain of 2 (OL-135) and representative oxazole C5 substituents were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH). Exceptionally potent and selective FAAH inhibitors emerged from the series (e.g., 6, K-i = 200 and 260 pM for rat and rhFAAH). With simple and small C5 oxazole substituents, each series bearing a biphenylethyl, phenoxyphenethyl, or (phenoxymethyl)phenethyl C2 side chain was found to follow a well-defined linear relationship between -log K-i and Hammett sigma(p) of a magnitude (rho = 2.7-3.0) that indicates that the substituent electronic effect dominates, confirming its fundamental importance to the series and further establishing its predictive value. Just as significantly, the nature of the C5 oxazole substituent substantially impacts the selectivity of the inhibitors whereas the effect of the C2 acyl chain was more subtle but still significant even in the small series examined. Combination of these independent features, which display generalized trends across a range of inhibitor series, simultaneously improves FAAH potency and selectivity and can provide exquisitely selective and potent FAAH inhibitors.